Cleared Traditional

K040120 - DIASORIN LIAISON EBNA IGG, LIAISON VCA IGG, LIAISON VCA IGM ASSAYS

K040120 is an FDA 510(k) clearance for DIASORIN LIAISON EBNA IGG, manufactured by DiaSorin, Inc.. The device is a Class 1 Microbiology device with product code LLM cleared through the Traditional 510(k) pathway after a 465-day FDA review.

K040120 · DiaSorin, Inc. · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2005
Decision
465d
Days
Class 1
Risk

K040120 is an FDA 510(k) clearance for the DIASORIN LIAISON EBNA IGG, LIAISON VCA IGG, LIAISON VCA IGM ASSAYS. Classified as Test, Antigen, Nuclear, Epstein-barr Virus (product code LLM), Class I - General Controls.

Submitted by DiaSorin, Inc. (Stillwater, US). The FDA issued a Cleared decision on April 29, 2005 after a review of 465 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3235 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Microbiology submissions.

View all DiaSorin, Inc. devices

FDA 510(k) Submission Details - K040120

510(k) Number K040120 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 20, 2004
Decision Date April 29, 2005
Days to Decision 465 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
363d slower than avg
Panel avg: 102d · This submission: 465d
Pathway characteristics
Predicate-based equivalence.

LLM Device Classification - Class 1, General Controls

Product Code LLM Test, Antigen, Nuclear, Epstein-barr Virus
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 866.3235
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.

Regulatory Peers - LLM Test, Antigen, Nuclear, Epstein-barr Virus

All 21
Devices cleared under the same product code (LLM) and FDA review panel - the closest regulatory comparables to K040120.
ADVIA Centaur EBV-EBNA IgG
K233605 · Biokit, S.A. · Aug 2024
THE APTUS (AUTOMATED) APPLICATION OF THE EBNA IGG ELISA TEST SYSTEM. AN ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) FOR TH
K984133 · Zeus Scientific, Inc. · Jan 1999
IMMUNOWELL EBNA IGG TEST
K973941 · Genbio · Aug 1998
EBNA-1 IGM ELISA TEST SYSTEM
K980598 · Clark Laboratories, Inc. · May 1998
EBNA IGG EIA TEST SYSTEM
K951549 · Immunoprobe, Inc. · Apr 1996
EBNA ENZYME IMMUNOASSAY KIT
K951822 · Granbio, Inc. · Feb 1996